OncoMatch/Clinical Trials/NCT07087002
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
Is NCT07087002 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including GPC2-CAR T cells and Fludarabine for medulloblastoma.
Treatment: GPC2-CAR T cells · Fludarabine · Cyclophosphamide — This is a single-site, open-label Phase 1 clinical trial evaluating the feasibility, safety, and preliminary activity of autologous GPC2-targeted chimeric antigen receptor (CAR) T cells administered via intracerebroventricular (ICV) infusion in children and young adults with relapsed or refractory medulloblastoma or other eligible Central Nervous System (CNS) embryonal tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Neuroblastoma
Biomarker criteria
Required: GPC2 overexpression (H-score ≥ 100 by IHC)
GPC2 Positive: H-score ≥ 100 by IHC staining performed ... at Stanford Clinical Anatomic Pathology Lab for GPC2 from a tumor sample any time since initial diagnosis.
Prior therapy
Must have received: curative-intent therapy — upfront
tumor progression or recurrence following initial diagnosis and upfront treatment with curative intent, or failure to achieve disease control with standard curative-intent therapy
Cannot have received: CAR-T cell therapy
Prior receipt of a chimeric antigen receptor (CAR)-based therapy.
Lab requirements
Blood counts
Hemoglobin ≥ 8 g/dL; ANC ≥ 1,000/μL; Platelet count ≥ 75,000/μL, with no platelet transfusion within 96 hours prior to enrollment; ALC ≥ 150/μL; PT/INR, PTT ≤ 1.5 x ULN for age
Kidney function
Serum creatinine < 1.5 x ULN for age and gender, OR creatinine clearance or GFR ≥ 70 mL/min/1.73 m2
Liver function
Serum ALT or AST ≤ 3x ULN; Total bilirubin ≤ 1.5 mg/dL, unless subject has Gilbert's Syndrome
Cardiac function
Cardiac ejection fraction ≥ 45%; No evidence of physiologically significant pericardial effusion as determined by an ECHO; No clinically significant ECG findings
Normal Organ and Marrow Function ... see full criteria for details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Lucile Packard Children's Hospital Stanford · Palo Alto, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify